PURPOSE: The main purpose was to examine longitudinally the influence of body mass index (BMI) and obesity on the development of breast cancer treatment-related lymphedema. We asked, does elevated BMI increase lymphedema risk? METHODS: A secondary analysis was conducted on de-identified data collected from 138 newly diagnosed breast cancer survivors who had arm-volume measurements and symptom assessment at pre-treatment baseline and measurements up to 30 months post-surgery in a prospective longitudinal parent study. Arm volume and weight data, part of the information collected during each participant visit, were examined. RESULTS: Breast cancer survivors whose BMI was ≥30 at the time of breast cancer treatment were approximately 3.6 times more likely to develop lymphedema at 6 months or greater after diagnosis than those with a BMI < 30 at the time of cancer treatment (95% confidence interval, C.I., for odds ratio, O.R., 1.42-9.04; p = 0.007). Those with a general BMI increase or a BMI rise to 30 or greater during their first 30 months of survivorship were not more likely to develop late-onset lymphedema than those who did not have similar changes in BMI. CONCLUSIONS: Pre-treatment BMI may be a risk factor for lymphedema. Weight gain post-treatment may not be. Further research is warranted.
PURPOSE: The main purpose was to examine longitudinally the influence of body mass index (BMI) and obesity on the development of breast cancer treatment-related lymphedema. We asked, does elevated BMI increase lymphedema risk? METHODS: A secondary analysis was conducted on de-identified data collected from 138 newly diagnosed breast cancer survivors who had arm-volume measurements and symptom assessment at pre-treatment baseline and measurements up to 30 months post-surgery in a prospective longitudinal parent study. Arm volume and weight data, part of the information collected during each participant visit, were examined. RESULTS:Breast cancer survivors whose BMI was ≥30 at the time of breast cancer treatment were approximately 3.6 times more likely to develop lymphedema at 6 months or greater after diagnosis than those with a BMI < 30 at the time of cancer treatment (95% confidence interval, C.I., for odds ratio, O.R., 1.42-9.04; p = 0.007). Those with a general BMI increase or a BMI rise to 30 or greater during their first 30 months of survivorship were not more likely to develop late-onset lymphedema than those who did not have similar changes in BMI. CONCLUSIONS: Pre-treatment BMI may be a risk factor for lymphedema. Weight gain post-treatment may not be. Further research is warranted.
Authors: Funda Meric; Thomas A Buchholz; Nadeem Q Mirza; Georges Vlastos; Frederick C Ames; Merrick I Ross; Raphael E Pollock; S Eva Singletary; Barry W Feig; Henry M Kuerer; Lisa A Newman; George H Perkins; Eric A Strom; Marsha D McNeese; Gabriel N Hortobagyi; Kelly K Hunt Journal: Ann Surg Oncol Date: 2002-07 Impact factor: 5.344
Authors: Nicole L Stout Gergich; Lucinda A Pfalzer; Charles McGarvey; Barbara Springer; Lynn H Gerber; Peter Soballe Journal: Cancer Date: 2008-06-15 Impact factor: 6.860
Authors: Kathryn H Schmitz; Marian L Neuhouser; Tanya Agurs-Collins; Krista A Zanetti; Lisa Cadmus-Bertram; Lorraine T Dean; Bettina F Drake Journal: J Natl Cancer Inst Date: 2013-08-29 Impact factor: 13.506
Authors: Ira L Savetsky; Jeremy S Torrisi; Daniel A Cuzzone; Swapna Ghanta; Nicholas J Albano; Jason C Gardenier; Walter J Joseph; Babak J Mehrara Journal: Am J Physiol Heart Circ Physiol Date: 2014-05-23 Impact factor: 4.733
Authors: Lauren S Jammallo; Cynthia L Miller; Marybeth Singer; Nora K Horick; Melissa N Skolny; Michelle C Specht; Jean O'Toole; Alphonse G Taghian Journal: Breast Cancer Res Treat Date: 2013-11 Impact factor: 4.872
Authors: Renate M Winkels; Kathleen M Sturgeon; Michael J Kallan; Lorraine T Dean; Zi Zhang; Margaret Evangelisti; Justin C Brown; David B Sarwer; Andrea B Troxel; Crystal Denlinger; Monica Laudermilk; Anna Fornash; Angela DeMichele; Lewis A Chodosh; Kathryn H Schmitz Journal: Contemp Clin Trials Date: 2017-07-21 Impact factor: 2.226
Authors: N LeVasseur; C Stober; K Daigle; A Robinson; S McDiarmid; S Mazzarello; B Hutton; A Joy; D Fergusson; J Hilton; M McInnes; M Clemons Journal: Curr Oncol Date: 2018-08-14 Impact factor: 3.677
Authors: M R Fu; C M Cleland; A A Guth; M Kayal; J Haber; F Cartwright; R Kleinman; Y Kang; J Scagliola; D Axelrod Journal: Lymphology Date: 2013-06 Impact factor: 1.286